CoChat

Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: Real‐world data analysis

Cahn, Avivit, Melzer‐Cohen, Cheli, Pollack, Rena, Chodick, Gabriel, Shalev, Varda · 2019 · Diabetes, Obesity and Metabolism
Cited by 85

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aim: To assess the possible risk of acute kidney injury (AKI) with the use of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐i) as well as changes in estimated glomerular filtration rate (eGFR), hospitalizations and mortality in a real‐world setting. Materials and methods: Included in this historical cohort study were patients with type 2 diabetes in a large health organization in Israel who initiated therapy with SGLT2‐i or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) during 1 April 2015 to 30 June 2017. We collected data on serum creatinine measurements taken between 180 days prior to and 24 weeks after therapy initiation. Study endpoints included ≥30% reduction in eGFR, hospitalization with AKI, any hospitalization and all‐cause mortality. Results: Overall 6418 and 5604 patients initiated SGLT2‐i and DPP‐4i, respectively. Baseline mean (SD) eGFR was higher among the SGLT2‐i group compared with the DPP‐4i group (88.3 [17.4] and 82.8 [23.7], respectively) but were similar when stratifying by chronic kidney disease (CKD) stages. The adjusted odds ratio (OR) (95% confidence interval [CI]) for ≥30% reduction in eGFR with SGLT2‐i versus DPP4‐i was 0.70 (0.49‐1.00) and ORs ranged from 1.97 (0.62‐6.26) to 0.45 (0.21‐0.99) in patients with baseline eGFR 30 to 45 and ≥90 mL/min/1.73 m 2 , respectively. Risks of AKI (OR = 0.47, 95% CI 0.27‐0.80), hospitalization (OR = 0.66, 95% CI 0.56‐0.78) or all‐cause mortality (OR = 0.43, 95% CI 0.20‐0.95) were lower in patients initiating SGLT2‐i versus DPP‐4i. Conclusions: This real‐world data analysis supports reassuring findings from previous randomized clinical trials showing no increased AKI risk among SGLT2‐i users. Nevertheless, because of the more prominent decrease in eGFR in patients with moderate CKD, cautious use of SGLT2‐i in patients with reduced eGFR is advised.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13532

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 9

  1. 10.1056/NEJMra1214243 · DOI · Paper page
  2. 10.1007/s12325-017-0573-0 · DOI · Paper page
  3. 10.1111/dom.12917 · DOI · Paper page
  4. 10.1161/JAHA.117.007165 · DOI · Paper page
  5. 10.1016/j.numecd.2017.10.011 · DOI
  6. 10.1111/dom.12654 · DOI · Paper page
  7. 10.1007/s40620-017-0423-9 · DOI · Paper page
  8. 10.1056/NEJMcibr1608564 · DOI · Paper page
  9. 10.14740/jocmr2760w · DOI · Paper page

Cited by

Metadata

Authors
Cahn, A., Melzer‐Cohen, C., Pollack, R., Chodick, G., & Shalev, V.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-10-15
Volume
21
Issue
2
Pages
340-348
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2890282628
Cited by
85
References
7
FWCI
7.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.